10Jul
Proactive Due Diligence Considerations for Life Sciences Dealmakers
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the science itself and, as a...
By:
McDermott Will & Emery
Related
Wilson Sonsini Goodrich & Rosati (Wilson Sonsini) is pleased to present its 2019 Antitrust Year in R...
Read More >
Companies that contribute to multiemployer pension plans are often rightfully worried that corporate...
Read More >
The COVID-19 pandemic is impacting every facet of the economy, including commercial construction and...
Read More >
Although COVID-19 is rightfully viewed primarily as a public health and humanitarian issue, it is wo...
Read More >
The Alabama Department of Environmental Management (“ADEM”) and Martin-Aycock Properties, LLC, (“...
Read More >
While the impact of the COVID-19 pandemic on the real estate development industry remains unclear, s...
Read More >